-
1
-
2
-
3
Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer
Published 2023-11-01Get full text
Article -
4
Author Correction: Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer
Published 2023-12-01Get full text
Article -
5
-
6
-
7
Utilizing herbarium specimens to assist with the listing of rare plants
Published 2023-08-01Get full text
Article -
8
-
9
-
10
Body mass, blood pressure, and cognitive functioning among octogenarians and centenarians
Published 2023-09-01Get full text
Article -
11
-
12
Strength Performance of Nonwoven Coir Geotextiles as an Alternative Material for Slope Stabilization
Published 2023-06-01Get full text
Article -
13
The impacts of deacetylation prior to dilute acid pretreatment on the bioethanol process
Published 2012-02-01Get full text
Article -
14
Protocol for the implementation of a statewide mobile addiction program
Published 2023-03-01Article -
15
Adverse childhood experiences and hormonal contraception: Interactive impact on sexual reward function.
Published 2023-01-01Get full text
Article -
16
Differential expression of NF-κB heterodimer RelA/p50 in human urothelial carcinoma
Published 2018-09-01Get full text
Article -
17
Palbociclib Adherence and Persistence in Patients with Hormone Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer
Published 2023-04-01“…Nicole M Engel-Nitz,1 Mary G Johnson,1 Michael P Johnson,1 Ashley S Cha-Silva,2 Samantha K Kurosky,2 Xianchen Liu2 1Optum, Eden Prairie, MN, 55344, USA; 2Pfizer Inc, New York, NY, 10017, USACorrespondence: Nicole M Engel-Nitz, HEOR | Optum Life Sciences, MN950-1000, 11000 Optum Circle, Eden Prairie, MN, 55344, USA, Tel +1 952-205-7770, Email Nicole.engel-nitz@optum.comPurpose: To assess adherence and persistence with palbociclib therapy in patients with HR+/HER2- metastatic breast cancer (mBC) in a US real-world setting.Methods: This retrospective study evaluated palbociclib dosing, adherence, and persistence using commercial and Medicare Advantage with Part D claims data from the Optum Research Database. …”
Get full text
Article -
18
-
19
-
20
Maternal adverse childhood experiences impact fetal adrenal volume in a sex-specific manner
Published 2023-02-01Get full text
Article